EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH JUVENILE POLYARTERITIS
Abstract
Key words: children, nodular polyarteritis, rituximab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (2): 193–200)
About the Authors
E.I. AlexeevaRussian Federation
T.V. Sleptsova
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
K.B. Isaeva
Russian Federation
R.V. Denisova
Russian Federation
E.V. Mitenko
Russian Federation
References
1. Лыскина Г.А. Узелковый полиартериит. Детская ревматология. Под общей ред. А.А. Баранова, Л.К. Баженовой. М.: Медицина. 2002. С. 228–243.
2. Лыскина Г.А. Узелковый полиартериит. Кардиология и ревматология детского возраста. Под общей ред. Г.А. Самсыгиной, М.Ю. Щербаковой. М. 2004. С. 228–243.
3. Исаева Л.А., Лыскина Г.А. Узелковый полиартериит у детей. М.: Медицина. 1984. С. 5–11, 48–165.
4. Dillon M.J. Vasculitis treatment — new therapeutic approaches. Eur. J. Pediatr. 2006; 165: 351–357.
5. Langford C.A. Small vessel vasculitis: therapeutic management. Curr. Rheumatol. Rep. 2007; 9: 328–335.
6. Wright E., Dillon M.J., Tullus K. Childhood vasculitis and plasma exchange. Eur. J. Pediatr. 2007; 166: 145–151.
7. Brogan P.A., Dillon M.J. The use of immunosuppressive and cytotoxic drugs in non-malignant disease. Arch. Dis. Child. 2000; 83: 259–264.
8. Jayne D. How to induce remission in primary systemic vasculitis. Best Pract. Res. Clin. Rheumatol. 2005; 19: 293–305.
9. Noorchashm H., Noorchashm N., Kern J. et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997; 46: 941–946.
10. Chan O.T., Hannum L.G., Haberman A.M. et al. A novel mouse with B cells but lacking serum antibody reveals an antibodyindependent role for B cells in murine lupus. J. Exp. Med. 1999; 189: 1639–1648.
11. Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001; 167: 1072–1080.
12. O’Neill S.K., Shlomchik M.J., Glant T.T. et al. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005; 174: 3781–3788.
13. Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm. Res. 1996; 45: 91–95.
14. Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin. Rheumatol. 1998; 17: 505–510.
15. Anolik J.H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004; 50: 3580–3590.
16. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005; 257: 540–548.
17. Aries P.M., Hellmich B., Voswinkel J. et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 2006; 6: 853–858.
18. Smith K.G., Jones R.B., Burns S.M. et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and retreatment. Arthritis Rheum. 2006; 54: 2970–2982.
19. Stasi R., Stipa E., Del P.G. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006; 45: 1432–1436.
20. Keogh K.A., Ytterberg S.R., Fervenza F.C. et al. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open label pilot trial. Am. J. Respir. Crit. Care Med. 2006; 173: 180–187.
21. Keogh K.A., Wylam M.E., Stone J.H. et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory anti–neutrophil cytoplasmic аnti–body associated vasculitis. Arthritis Rheum. 2005; 52: 262–268.
22. Omdal R., Wildhagen K., Hansen T. et al. Anti–CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand. J. Rheumatol. 2005; 34: 229–232.
23. Jansson A.F., Sengler C., Kummerle–Deschner J. B–cell depletion for autoinflammatory diseases in pediatric patients a retrospective study. Ann. Rheum. Dis. 2009; 68 (3): 300.
24. El–hallak M., Binstadt B.A., Leichtner A.M. et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J. Pediatr. 2007; 150 (4): 376–382.
25. Binstadt B., Caldas A., Stuart E. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J. Pediatr. 2003; 143: 598–604.
26. Polido–Pereira J., Ferreira D., Rodrigues A. et al. Rituximab use in pediatric autoimmune diseases: four case reports. Ann. NY. Acad. Sci. 2009; 1173: 712–720.
27. Eriksson P. Nine patients with anti–neutrophil cytoplasmic antibody positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005; 257: 540–548.
Review
For citations:
Alexeeva E., Sleptsova T., Valieva S., Bzarova T., Isaeva K., Denisova R., Mitenko E. EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH JUVENILE POLYARTERITIS. Current Pediatrics. 2011;10(2):193-200.
Email this article 
